Charles Herzog, Charles A. Herzog, M.D., FACC, FAHA

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Individual stocks and stock options
    Ineligible company:
    Boston Scientific
    Topic:
    Cardiac device therapy
    Date added:
    10/25/2026
    Date updated:
    10/25/2026
    Relationship end date:
    01/01/2027
  • Attribution:
    Self
    Type of financial relationship:
    Individual stocks and stock options
    Ineligible company:
    Johnson&Johnson
    Topic:
    Pharmaceuticals
    Date added:
    10/25/2026
    Date updated:
    10/25/2026
    Relationship end date:
    01/01/2027
  • Attribution:
    Self
    Type of financial relationship:
    Individual stocks and stock options
    Ineligible company:
    Merck
    Topic:
    Pharmaceuticals
    Date added:
    10/25/2026
    Date updated:
    10/25/2026
    Relationship end date:
    01/01/2027
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Merck
    Topic:
    Pharmaceuticals
    Date added:
    10/25/2026
    Date updated:
    10/25/2026
    Relationship end date:
    12/31/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Novo Nordisk
    Topic:
    Pharmaceuticals
    Date added:
    10/25/2026
    Date updated:
    10/25/2026
    Relationship end date:
    01/01/2028
  • Attribution:
    Self
    Type of financial relationship:
    Individual stocks and stock options
    Ineligible company:
    Pfizer
    Topic:
    Pharmaceuticals
    Date added:
    10/25/2026
    Date updated:
    10/25/2026
    Relationship end date:
    01/01/2028
  • Attribution:
    Self
    Type of financial relationship:
    Royalties or patent beneficiary
    Ineligible company:
    UpToDate
    Topic:
    CKD and Heart Disease
    Date added:
    10/25/2026
    Date updated:
    10/25/2026
    Relationship end date:
    01/01/2029
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Astra-Zeneca
    Topic:
    Pharmaceuticals
    Date added:
    10/25/2026
    Date updated:
    10/25/2026
    Relationship end date:
    12/31/2029
Return to Midwest Cardiovascular Forum 2026